QVAR 40
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QVAR 40 (QVAR 40).
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
| Metabolism | Beclomethasone dipropionate is metabolized primarily by esterase enzymes to the active metabolite beclomethasone-17-monopropionate, which is further metabolized by CYP3A4 to inactive metabolites. |
| Excretion | Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged. |
| Half-life | Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma. |
| Protein binding | 98% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd is approximately 0.6 L/kg, indicating distribution into total body water. |
| Bioavailability | Inhalation: absolute bioavailability is approximately 22% of the nominal dose due to deposition in the lungs and gastrointestinal tract; oral bioavailability is less than 1% due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: 24 hours for clinical improvement in asthma symptoms; maximal effect observed after 1-2 weeks of regular use. |
| Duration of Action | Duration of action is 12 hours after a single dose, supporting twice-daily dosing for maintenance therapy. |
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
| Dosage form | AEROSOL, METERED |
| Renal impairment | No dose adjustment required; pharmacokinetics not significantly altered in renal impairment. |
| Liver impairment | No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment due to potential increased systemic exposure. |
| Pediatric use | Children 5-11 years: 40-80 mcg inhaled twice daily; maximum 160 mcg/day. Children 12 years and older: same as adult. |
| Geriatric use | Start at lower end of dosing range (40 mcg twice daily); monitor for local adverse effects; no specific dose adjustment required based on age alone. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QVAR 40 (QVAR 40).
| Breastfeeding | Beclomethasone dipropionate is excreted into breast milk in minimal amounts, expected to be low due to inhalation route and high protein binding. The M/P ratio is not specifically reported for beclomethasone. The American Academy of Pediatrics considers inhaled corticosteroids compatible with breastfeeding. However, use the lowest effective dose to minimize infant exposure. |
| Teratogenic Risk | QVAR 40 (beclomethasone dipropionate) is an inhaled corticosteroid. Based on human data from large cohort studies and meta-analyses, inhaled corticosteroids at recommended doses are not associated with a significant increase in major congenital malformations. However, there is a potential risk of reduced fetal growth and low birth weight with high doses. First trimester: no clear teratogenic risk. Second and third trimesters: risk of intrauterine growth restriction (IUGR) and adrenal suppression in the fetus if maternal use is prolonged at high doses. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to beclomethasone dipropionate or any component; primary treatment of status asthmaticus or acute asthma exacerbations.
| Precautions | Localized oral and pharyngeal infections with Candida albicans; paradoxical bronchospasm; hypothalamic-pituitary-adrenal axis suppression with excessive doses; reduction in growth velocity in children; need to switch to systemic corticosteroids during stress or severe asthma exacerbation; careful monitoring for patients with systemic corticosteroid withdrawal; potential for eosinophilic conditions; avoiding use in patients with active or quiescent tuberculosis, untreated fungal, bacterial, or viral infections, or ocular herpes simplex. |
Loading safety data…
| Fetal Monitoring | Monitor maternal asthma control (peak expiratory flow, symptoms, exacerbations). For fetal growth, consider serial ultrasound assessments of fetal growth in women requiring high doses or with severe asthma. Monitor for maternal adrenal insufficiency if prolonged high-dose therapy is used. No specific fetal monitoring required at standard doses. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at inhaled doses up to 10 times the maximum recommended human daily inhalation dose. Asthma control itself is important for reproductive outcomes. |